Skip to main content
Clinical Trials/ISRCTN15475780
ISRCTN15475780
Active, not recruiting
未知

The effect of microbiome manipulation through diet and Fecal Microbial Transplant (FMT) in inducing and maintaining remission in patients with mild to moderate ulcerative colitis: open label randomized controlled trial

All India Institute of Medical Sciences0 sites66 target enrollmentMarch 16, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Mild to moderate ulcerative colitis
Sponsor
All India Institute of Medical Sciences
Enrollment
66
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35973787/ (added 17/08/2022)

Registry
who.int
Start Date
March 16, 2022
End Date
October 15, 2022
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Age between 18 – 65 years
  • 2\. Patients with mild to moderate ulcerative colitis as assessed by simple clinical colitis activity index (SCCAI, 3 – 9\) of any disease extent along with active disease on endoscopy (ulcerative colitis index of severity, UCEIS \>1\)
  • 3\. Patients on stable doses of 5\-ASA (5\-amino salicylic acid) for past 4 weeks
  • 4\. Patients on stable doses of azathioprine/6\-mercaptopurine for past 3 months
  • 5\. Patients who received biologics 6 months ago
  • 6\. Patients on stable doses of topical therapy for past 2 weeks
  • 7\. Patients on oral steroids (equivalent dose of prednisolone \<20 mg/day)
  • 8\. Patients giving consent for FMT
  • 9\. Patients who agree to adhere to the diet schedule

Exclusion Criteria

  • 1\. Patients with severe disease activity
  • 2\. Patients who have received topical 5\-ASA or topical steroids in the past 2 weeks
  • 3\. Patients with H/O of antibiotic or probiotic exposure in the past 4 weeks
  • 4\. Patients requiring hospitalization
  • 5\. Patients with H/O bowel surgery
  • 6\. Patients with concomitant GI infection
  • 7\. Pregnancy
  • 8\. Patients with other comorbid illnesses

Outcomes

Primary Outcomes

Not specified

Similar Trials